Table 4 Overall analysis of miR-20a expression association with clinicopathological characteristics
From: MiR-20a, a novel promising biomarker to predict prognosis in human cancer: a meta-analysis
Clinicopathological parameters | No. of studies | No. of patients | Pooled OR (95%CI) | Heterogeneity | ||
|---|---|---|---|---|---|---|
Fixed | Random | I2 | p-value | |||
Gender (male vs. female) | 7 | 1103 | 0.69(0.51,0.92) | 0.74(0.50,1.09) | 30.70% | 0.194 |
Age (≥60 vs < 60 years) | 3 | 202 | 1.44(0.81,2.55) | 1.44(0.81,2.57) | 0.00% | 0.373 |
Tumor Size (≥5 vs < 5 cm) | 4 | 422 | 0.76(0.51,1.12) | 0.77(0.44,1.36) | 49.20% | 0.116 |
Lymph node metastasis (absent vs.present) | 3 | 260 | 1.11(0.68,1.81) | 1.03(0.48,2.21) | 54.30% | 0.112 |
TNM stage(III + IV vs. I + II) | 5 | 467 | 0.96(0.66,1.41) | 1.15(0.51,2.58) | 74.40% | 0.004 |
Differentiation (poor vs. others) | 6 | 951 | 1.50(1.06,2.13) | 1.34(0.73,2.44) | 59.10% | 0.032 |